XOMA Royalty Corp
Price data unavailable
Track XOMA in your trading journalAbout XOMA Royalty Corp
XOMA Royalty Corp (XOMA) is a US-listed equity tracked across major market indices. XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
The company reports trailing twelve-month revenue of $12.32M and net income of $4.46M. Key metrics include a return on equity of 4.8%, a debt-to-equity ratio of 1.71.
FINOTAUR provides free research summaries, news aggregation, and fundamentals for XOMA to support both active traders and long-term investors.
Fundamentals
| Revenue (TTM) | $12.32M |
| Net Income (TTM) | $4.47M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | 4.81% |
| Debt-to-Equity | 1.71 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·May 14
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)
- GlobeNewswire Inc.·May 7
Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders
- GlobeNewswire Inc.·Apr 28
XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm
Want real-time analysis on XOMA?
Track it free in your trading journal. Log trades, tag setups, and review your edge.